Indaptus Therapeutics is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, which Co. refers to as the Accordion Pill. Co.'s primary product candidate, Accordion Pill Carbidopa/Levodopa is being developed for the indication of treatment of Parkinson's disease symptoms in Parkinson's disease patients. In addition, Co. has initiated a clinical development program for its Accordion Pill platform with the two primary cannabinoids contained in cannabis sativa, which it refers to as AP-Cannabinoids. Co. is formulating and testing Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. The INDP stock yearly return is shown above.
The yearly return on the INDP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INDP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|